Inretio presents initial clinical trial results at prestigious BRAIN Conference 2024 in London.

Toronto, Ontario--(Newsfile Corp. - December 11, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, congratulates its investment partner Inretio on the success of the first phase of the PREVA ischemic stroke device.

Per Inretio's LinkedIn post and formal press announcement, key collaborator Dr. Gal Yaniv, Director of Endovascular Neurosurgery from Sheba Medical Center, presented compelling findings from the first phase of the PREVA device clinical study. The ischemic stroke device results demonstrated exceptional clinical outcomes, validating the potential to reshape stroke care and improve patient recovery.

During the clinical trials, patients treated with the PREVA device showed excellent outcomes, which underscore Inretio's commitment to enhancing stroke treatment. Per the announcement, "Each data point reflects more than just success in the lab-it represents a life changed, a family impacted, and a future restored." Raviv Vine, CEO of Inretio, expressed "Our mission is driven by the belief that behind every medical innovation is the opportunity to save lives and offer hope." The presentation at BRAIN Conference marks a critical step forward for Inretio as it continues to advance its clinical program and move closer to bringing this life-changing technology to the global market.

"We're excited that Dr. Yaniv has achieved success during the initial clinical trial of Inretio's PREVA Ischemic Stroke device," shared Rob Fia, CEO of Therma Bright. " We look forward to receiving more updates from our partner on their progress, and look to inform our shareholders as these successes are delivered."

Inretio and Therma Bright will provide further updates to the market, as progress is made through the clinical trials.

About Inretio:

Inretio is an Israeli-based medical device company dedicated to revolutionizing ischemic stroke treatment through innovative clot-retriever technology. Its flagship product, the PREVA device, ensnares and removes clots, minimizing complications like clot fragmentation and downstream embolism. Inretio's mission is to enhance stroke treatment outcomes for patients, physicians, and healthcare systems worldwide. Visit: .

About Therma Bright Inc.

Therma Bright is a developer and partner in a wide range of leading edge, proprietary diagnostic and medical device technologies focused on providing consumers and medical professionals with quality, innovative solutions that address some of today's most important medical and healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: .

Follow us on Twitter

FORWARD-LOOKING STATEMENTS

Certain statements in this news release constitute "forward-looking" statements. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.